Author:
Jayaprakasam Vetri Sudar,Bodei Lisa
Funder
National Institutes of Health
Subject
Radiology, Nuclear Medicine and imaging,General Medicine,Radiation
Reference110 articles.
1. Phase 3 trial of (177)Lu-DOTATATE for midgut neuroendocrine tumors;Strosberg;N Engl J Med,2017
2. (177)Lu-DOTATATE plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial;Strosberg;Lancet Oncol,2021
3. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy;Krenning;Ann Oncol,1999
4. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours;Bodei;Eur J Nucl Med Mol Imaging,2013
5. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours;Bodei;Eur J Nucl Med Mol Imaging,2004